Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib

Sunitinib and other targeted therapies for renal cell carcinoma

(2011) T Powles et al.   BRITISH JOURNAL OF CANCER

Protocol Information Provides Opportunity for Patient Safety and Quality Improvement

(2011) Thomas J. George et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

How to select targeted therapy in renal cell cancer

(2010) B. Escudier et al.   ANNALS OF ONCOLOGY

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

(2010) Manuela Schmidinger et al.   CANCER TREATMENT REVIEWS

Experience with sorafenib and adverse event management

(2010) Joaquim Bellmunt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

(2008) A A M van der Veldt et al.   BRITISH JOURNAL OF CANCER